KR910018387A - 약제학적 화합물 - Google Patents

약제학적 화합물 Download PDF

Info

Publication number
KR910018387A
KR910018387A KR1019910006544A KR910006544A KR910018387A KR 910018387 A KR910018387 A KR 910018387A KR 1019910006544 A KR1019910006544 A KR 1019910006544A KR 910006544 A KR910006544 A KR 910006544A KR 910018387 A KR910018387 A KR 910018387A
Authority
KR
South Korea
Prior art keywords
compound
methyl
formula
thieno
piperazinyl
Prior art date
Application number
KR1019910006544A
Other languages
English (en)
Other versions
KR100195566B1 (ko
Inventor
쿠마르 샤크라바티 지반
마이클 호튼 테렌스
에드워드 터퍼 데이비드
Original Assignee
티.알.크로터
릴리 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910018387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 티.알.크로터, 릴리 인더스트리즈 리미티드 filed Critical 티.알.크로터
Publication of KR910018387A publication Critical patent/KR910018387A/ko
Application granted granted Critical
Publication of KR100195566B1 publication Critical patent/KR100195566B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

내용 없음

Description

약제학적 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 2-메틸-10-(4-메틸-1-피페라지닐)-4H-티에노〔2,3-b〕〔1,5〕벤조디아제핀 또는 이의 산 부가염.
  2. 2-메틸-10-(4-메틸-1-피페라지닐)-4H-티에노〔2,3-b〕〔1,5〕벤조디아제핀.
  3. 제1항에 따르면 화합물 또는 약제학적으로 무독한 이의 산 부가염을 약제학적으로 무독한 희석제 또는 담체와 함께 포함함을 특징으로 하는 약학 조성물.
  4. 제2항의 화합물 2.5 내지 5mg을 약제학적으로 무독한 희석제 또는 담체와 함께 포함함을 특징으로 하는 캅셀 또는 정제 형태의 약학 조성물.
  5. (a) N-메틸피페라진을 다음 일반식(Ⅱ)의 화합물과 반응시키거나,(b) 다음 구조식(Ⅲ)의 화합물을 페환시킴을 특징으로 하여 제1항에 따르는 화합물을 제조하는 방법.
    상기식에서, Q는 이탈 가능한 라디칼이다.
  6. 다음 일반식(Ⅱ)의 화합물 및 Q가 -NH2인 경우 이의 염.
    상기식에서, Q는 -NH2-OH 또는 -SH이다.
  7. 다음 일반식(Ⅸ)의 화합물.
    상기식에서, R은 에스테르 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910006544A 1990-04-25 1991-04-24 약제학적 화합물 KR100195566B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds
GB9009229.7 1990-04-25

Publications (2)

Publication Number Publication Date
KR910018387A true KR910018387A (ko) 1991-11-30
KR100195566B1 KR100195566B1 (ko) 1999-06-15

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910006544A KR100195566B1 (ko) 1990-04-25 1991-04-24 약제학적 화합물

Country Status (33)

Country Link
EP (1) EP0454436B1 (ko)
JP (1) JP2527860B2 (ko)
KR (1) KR100195566B1 (ko)
CN (1) CN1028429C (ko)
AT (1) ATE127804T1 (ko)
AU (1) AU643267B2 (ko)
BG (1) BG61710B2 (ko)
CA (1) CA2041113C (ko)
CY (1) CY1900A (ko)
CZ (1) CZ279937B6 (ko)
DE (3) DE69112895T4 (ko)
DK (1) DK0454436T3 (ko)
ES (1) ES2078440T3 (ko)
FI (1) FI101379B1 (ko)
GB (1) GB9009229D0 (ko)
GE (1) GEP20032965B (ko)
GR (1) GR3017877T3 (ko)
HK (1) HK87596A (ko)
HU (2) HU212416B (ko)
IE (1) IE68401B1 (ko)
IL (2) IL97912A (ko)
LU (2) LU90009I2 (ko)
LV (1) LV10262B (ko)
MX (1) MX173791B (ko)
NL (2) NL970015I2 (ko)
NO (3) NO178766C (ko)
NZ (1) NZ237932A (ko)
PT (1) PT97446B (ko)
RU (1) RU2043992C1 (ko)
SI (1) SI9110739A (ko)
SK (1) SK279196B6 (ko)
YU (1) YU48049B (ko)
ZA (1) ZA913085B (ko)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ATE198891T1 (de) * 1992-05-29 2001-02-15 Lilly Co Eli Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
PL189714B1 (pl) * 1995-05-30 2005-09-30 Lilly Co Eli Zastosowanie 2-metylo-4-(4-metylo-1-piperazynylo)-10H-tieno[2,3-b] [1,5]benzodiazepiny
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
CA2240836A1 (en) * 1995-12-21 1997-07-03 Pierre Van Tran Method for treating dermatitis
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CA2266444C (en) * 1996-09-23 2007-01-09 Eli Lilly And Company Olanzapine dihydrate d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1999011647A1 (fr) * 1997-09-02 1999-03-11 Yoshitomi Pharmaceutical Industries, Ltd. Composes thiophene condenses et leur utilisation en medecine
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
CN1239158C (zh) * 1997-09-30 2006-02-01 伊莱利利公司 2－甲基－噻吩并－苯并二氮杂䓬制剂
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
IL154688A0 (en) 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
US6906062B2 (en) * 2001-12-24 2005-06-14 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
US20040063694A1 (en) * 2002-06-05 2004-04-01 Browder Monte R. Compound useful for the treatment of CNS disorders
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
CA2551806A1 (en) 2003-12-22 2005-07-14 Teva Pharmaceutical Industries, Ltd. Methods of preparing olanzapine
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
WO2005070937A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. A process for making olanzapine in a polymorph form i
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
WO2006073886A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Olanzapine pamoate dihydrate
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Improved processes for the synthesis of olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (en) 2011-02-14 2012-08-15 Labtec GmbH Rapidly disintegrating oral film formulation for Olanzapin
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
EA201590048A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение оланзапина у животных
EP2879519A1 (en) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. A method for increasing meat and milk production
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
NL970015I2 (nl) 1997-09-01
IE911348A1 (en) 1991-11-06
IL112575A0 (en) 1995-05-26
BG61710B2 (bg) 1998-03-31
GB9009229D0 (en) 1990-06-20
YU73991A (sh) 1994-01-20
RU2043992C1 (ru) 1995-09-20
DE69112895T2 (de) 1996-03-07
PT97446B (pt) 1997-07-31
CA2041113C (en) 1998-07-14
HK87596A (en) 1996-05-24
LV10262B (en) 1995-04-20
CY1900A (en) 1991-04-24
HU212416B (en) 1996-06-28
MX173791B (es) 1994-03-25
GEP20032965B (en) 2003-05-12
NO178766B (no) 1996-02-19
HUT60503A (en) 1992-09-28
DE19675046I2 (de) 2001-05-23
DE69112895T4 (de) 2009-11-12
FI101379B (fi) 1998-06-15
GR3017877T3 (en) 1996-01-31
CS9101168A2 (en) 1991-12-17
SI9110739A (en) 1997-10-31
YU48049B (sh) 1996-10-18
NO911624L (no) 1991-10-28
CN1056693A (zh) 1991-12-04
IL97912A (en) 1995-10-31
DK0454436T3 (da) 1995-11-13
FI911986A0 (fi) 1991-04-24
IE68401B1 (en) 1996-06-12
AU7518691A (en) 1991-11-07
FI911986A (fi) 1991-10-26
NO178766C (no) 1996-05-29
NL300078I1 (nl) 2002-03-01
NL970015I1 (nl) 1997-06-02
SK279196B6 (sk) 1998-07-08
NO2001028I1 (no) 2002-01-28
HU911372D0 (en) 1991-10-28
KR100195566B1 (ko) 1999-06-15
NO911624D0 (no) 1991-04-24
HU211575A9 (en) 1995-12-28
LV10262A (lv) 1994-10-20
CA2041113A1 (en) 1991-10-26
MX25502A (es) 1993-10-01
NZ237932A (en) 1993-08-26
FI101379B1 (fi) 1998-06-15
CZ279937B6 (cs) 1995-09-13
DE69112895D1 (de) 1995-10-19
EP0454436B1 (en) 1995-09-13
JP2527860B2 (ja) 1996-08-28
LU90869I2 (fr) 2002-02-21
LU90009I2 (fr) 1997-01-31
ES2078440T3 (es) 1995-12-16
EP0454436A1 (en) 1991-10-30
ZA913085B (en) 1992-12-30
JPH0789965A (ja) 1995-04-04
CN1028429C (zh) 1995-05-17
PT97446A (pt) 1992-01-31
ATE127804T1 (de) 1995-09-15
IL97912A0 (en) 1992-06-21
AU643267B2 (en) 1993-11-11
NO1997005I1 (no) 1997-05-12

Similar Documents

Publication Publication Date Title
KR910018387A (ko) 약제학적 화합물
DK0379979T3 (ko)
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
ES8506635A1 (es) Un procedimiento para la preparacion de derivados de acilmorfinano
PT85411A (en) 7-]]3-(aminomethyl)-3-alkyl"-1-pyrrolidinyl"-quinoline-carboxylic acids
DE3360589D1 (en) 4"-epi erythromycin a and derivatives thereof as useful antibacterial agents
ES8501410A1 (es) Un procedimiento para la preparacion de nuevos derivados de fosfolipidos.
ES2094913T3 (es) Metodo para la preparacion de 3-amino-2-cloro-4-alquilpiridinas.
KR870007181A (ko) 피롤로[1,2-a] [4,1] 벤즈옥사제핀 유도체
ATE86993T1 (de) Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
AU658175B2 (en) Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
KR910020018A (ko) 피리도[3, 4-b] 피롤로[1, 2-e][1, 4, 5]옥사디아제핀 및 이의 관련 동족체 이의 제조방법 및 약제로서의 이의 용도
FR2616149B1 (fr) Nouveau derive de l'acide benzo (b) thiophene - 7 carboxylique, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR900016228A (ko) 티아제토퀴놀린-3-카르복실산 유도체, 그것의 제조방법 및 그것을 유효성분으로 하는 의약
OA09471A (fr) "Nouvelles benzothiazolinones substituées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
KR920002613A (ko) 이환성 함유 황화합물
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure
KR890002165A (ko) 피롤로 [1,2-a][4,1]벤즈옥사제핀 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J204 Request for invalidation trial [patent]
J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20081001

Effective date: 20091231

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20100126

Effective date: 20101105

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

EXPY Expiration of term
J222 Remand (patent court)

Free format text: REMAND (PATENT COURT) FOR INVALIDATION

J303 Written judgement (supreme court)

Free format text: JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20101206

Effective date: 20120823

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20120912

Effective date: 20121129